Bissan Al - Lazikani

Dr. Al-Lazikani is a data scientist and drug discovery expert, formally trained in both molecular biology and computer science. Currently, she leads the Therapeutics Data Science Initiative at the University of Texas MD Anderson Cancer Center, where her goal is to maximize the use of AI to enhance the entire drug discovery and development pathway. Dr. Al-Lazikani is also a co-lead at MD Anderson's Institute for Data Science in Oncology, where she is developing Digital Twins to optimize treatment options for patients. Previously, she led the development of canSAR.ai, the world's largest public cancer drug discovery platform, which helps inform target selection and prioritization for drug discovery. Dr. Al-Lazikani is a recipient of numerous awards including being Elected Fellow of the International Society for Computational Biology and the Royal Society of Biology.